阿托伐他汀钙联合缬沙坦治疗原发性高血压的临床研究

Clinical trial of atorvastatin calcium combined with valsartan in the treatment of essential hypertension

目的观察阿托伐他汀钙联合缬沙坦治疗原发性高血压的临床疗效及安全性。方法将130例原发性高血压患者随机分为对照组65例和试验组65例。对照组予以口服缬沙坦160 mg,qd;试验组在对照组的基础上,予以睡前口服阿托伐他汀钙20 mg。2组患者疗程均为12个月。比较2组患者的临床疗效、血清生长激素释放肽和同型半胱氨酸表达水平,以及不良反应的发生情况。结果治疗后,试验组的总有效率为86.15%显著高于对照组的41.54%(P<0.05)。治疗后,试验组的血清生长激素释放肽和同型半胱氨酸表达水平均显著低于对照组[(8.18±1.17)μg·L^(-1)vs(10.27±1.32)μg·L^(-1),(10.18±2.21)μmol·L^(-1)vs(18.57±2.64)μmol·L^(-1),P<0.01]。2组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论阿托伐他汀钙联合缬沙坦对原发性高血压患者的降压效果显著,且不增加不良反应的发生率。

Objective To evaluate the clinical efficacy and safety of atorvastatin calcium combined with valsartan in the treatment of essential hypertension. Methods One hundred and thirty patients with essential hypertension were randomly divided into control group （n = 65 ） and treat- ment group （n = 65 ）. Control group was given valsartan 160 mg, qd. Treatment group was received atorvastatin calcium 20 rag, every night on the basis of control group. The clinical efficacy, the expression levels of serum ghrelin and homocysteine, and the incidence of adverse drug reactions were compared between two groups. Results After treatment, the total effective rate of treatment group was significantly higher than that of control group （ 86. 15% vs 41.54%, P 〈 0. 05 ）. After treatment, the expression levels of serum serum ghrelin and homocysteine in treatment group were significantly lower than those in control group [（8. 18 ±1.17）μg . L-1 vs（10. 27 ± 1.32） μg . L-1, （10. 18 ±2.21） μmol . L-1 vs（18.57±2.64）μmol . L-1, P 〈0.01]. There was no significant difference in the incidence of adverse drug reactions between two groups （P 〉 0. 05 ）. Conclusion Atorvastatin calcium combined with valsartan have a definitive clinical efficacy for the treatment of essential hypertension, without increasing the incidence of adverse drug reactions.